SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 19, 2013
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(Registrants telephone number, including area code)
name or former, address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On November 19, 2013, Steven Lo, Vice President, Commercial Operations
of Corcept Therapeutics Incorporated (the Company), was promoted to the position of Senior Vice President and Chief Commercial Officer of the Company, effective immediately.
Mr. Lo, age 46, joined the Company as Vice President, Commercial Operations in September 2010. Mr. Lo has more than 19 years of
commercial experience in the pharmaceutical and biotechnology industry. From 1997 to 2010, Mr. Lo held various positions in marketing, sales and managed markets at Genentech, Inc., a biotechnology company that became a member of the Roche Group
in March 2009, most recently as Franchise Head, leading that companys endocrinology marketing and sales organization. Mr. Lo received his B.S. degree from the University of California, Davis and his Master of Health Administration from
the University of Southern California.
In connection with Mr. Los promotion, the board of directors of the Company approved an
increase in Mr. Los annual base salary to $385,000, effective immediately, and Mr. Lo was awarded an additional stock option to purchase 200,000 shares of the Companys common stock. The option award will vest in equal monthly
installments at the rate of 2.08334% per month over forty-eight (48) months, commencing on the first monthly anniversary of November 19, 2013. The exercise price per share for the option award is $1.92, the closing price of the
Companys common stock on The NASDAQ Stock Exchange on November 19, 2013.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|CORCEPT THERAPEUTICS INCORPORATED|
/s/ G. Charles Robb
||Name: G. Charles Robb|
||Title: Chief Financial Officer|
Date: November 25, 2013